Ancillary tests for hepatobiliary neoplasms: what we know and what we need to know.

Zhang, Sarah L; Wang, Hanlin L

Zhang, Sarah L; Wang, Hanlin L.

Affiliation

Zhang SL; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine and Ronald Reagan Medical Center, University of California at Los Angeles, Los Angeles, CA, 90095, USA.
Wang HL; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine and Ronald Reagan Medical Center, University of California at Los Angeles, Los Angeles, CA, 90095, USA. Electronic address: hanlinwang@mednet.ucla.edu.

Hum Pathol ; 141: 183-200, 2023 Nov.

Article in En | MEDLINE | ID: mdl-36775105

Subject(s)

Bile Duct Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Gastrointestinal Neoplasms; Liver Neoplasms; Humans; Bile Duct Neoplasms/diagnosis; Bile Duct Neoplasms/pathology; Liver Neoplasms/pathology; Cholangiocarcinoma/diagnosis; Cholangiocarcinoma/pathology; Carcinoma, Hepatocellular/diagnosis; Carcinoma, Hepatocellular/metabolism

Key words

Bile duct; Biomarker; Cholangiocarcinoma; Hepatocellular adenoma; Hepatocellular carcinoma; Metastatic carcinoma

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bile Duct Neoplasms / Cholangiocarcinoma / Carcinoma, Hepatocellular / Gastrointestinal Neoplasms / Liver Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Hum Pathol Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google